ImmunoGen
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The last earnings update was 16 days ago. More info.
Add to Portfolio Compare Print
- ImmunoGen has significant price volatility in the past 3 months.
IMGN Share Price and Events
7 Day Returns
1 Year Returns
IMGN Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| ImmunoGen (IMGN) | -2% | -23.1% | -66.3% | -81.8% | -65.8% | -83.3% |
| US Biotechs | 1% | -0% | -3.2% | -4.6% | 3.8% | 9.7% |
| US Market | 0.2% | -1.6% | 2.4% | 2.9% | 36.1% | 41% |
1 Year Return vs Industry and Market
- IMGN underperformed the Biotechs industry which returned -4.6% over the past year.
- IMGN underperformed the Market in United States of America which returned 2.9% over the past year.
IMGN Value
Is ImmunoGen undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
In this section, we usually try to help investors determine whether ImmunoGen is trading at an attractive price based on the cash flow it is expected to produce in the future. But as ImmunoGen has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
- It is not possible to calculate the future cash flow value for ImmunoGen. This is due to cash flow or dividend data being unavailable. The share price is $1.93.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for ImmunoGen's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
ImmunoGen's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2019-03-31) in USD | $-1.21 |
| NasdaqGS:IMGN Share Price ** | NasdaqGS (2019-05-22) in USD | $1.93 |
| United States of America Biotechs Industry PE Ratio | Median Figure of 35 Publicly-Listed Biotechs Companies | 19.23x |
| United States of America Market PE Ratio | Median Figure of 3,085 Publicly-Listed Companies | 17.79x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of ImmunoGen.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NasdaqGS:IMGN Share Price ÷ EPS (both in USD) = 1.93 ÷ -1.21 |
-1.6x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- ImmunoGen is loss making, we can't compare its value to the US Biotechs industry average.
- ImmunoGen is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does
ImmunoGen's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -1.6x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts |
7.3%per year |
| United States of America Biotechs Industry PEG Ratio | Median Figure of 28 Publicly-Listed Biotechs Companies | 1.26x |
| United States of America Market PEG Ratio | Median Figure of 2,123 Publicly-Listed Companies | 1.54x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for ImmunoGen, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
ImmunoGen's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2019-03-31) in USD | $-0.18 |
| NasdaqGS:IMGN Share Price * | NasdaqGS (2019-05-22) in USD | $1.93 |
| United States of America Biotechs Industry PB Ratio | Median Figure of 414 Publicly-Listed Biotechs Companies | 3.35x |
| United States of America Market PB Ratio | Median Figure of 5,201 Publicly-Listed Companies | 1.84x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NasdaqGS:IMGN Share Price ÷ Book Value per Share (both in USD) = 1.93 ÷ -0.18 |
-10.45x |
* Primary Listing of ImmunoGen.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- ImmunoGen has negative assets, we can't compare the value of its assets to the US Biotechs industry average.
Value checks
We assess ImmunoGen's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check) ImmunoGen has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
IMGN Future Performance
How is ImmunoGen expected to perform in the next 1 to 3 years based on estimates from 10 analysts?
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Unable to compare ImmunoGen's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
- Unable to compare ImmunoGen's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
- ImmunoGen's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NasdaqGS:IMGN Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts | 7.3% |
| NasdaqGS:IMGN Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 10 Analysts | 22.7% |
| United States of America Biotechs Industry Earnings Growth Rate | Market Cap Weighted Average | 22.6% |
| United States of America Biotechs Industry Revenue Growth Rate | Market Cap Weighted Average | 17.7% |
| United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 13.7% |
| United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7.3% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (1 month ago) | See Below |
| Future Estimates | Average of up to 10 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 96 | -33 | -107 | 7 |
| 2022-12-31 | 59 | -78 | -140 | 7 |
| 2021-12-31 | 46 | -120 | -154 | 8 |
| 2020-12-31 | 40 | -129 | -148 | 10 |
| 2019-12-31 | 40 | -112 | -158 | 8 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2019-03-31 | 42 | -106 | -174 |
| 2018-12-31 | 53 | -166 | -169 |
| 2018-09-30 | 79 | -155 | -140 |
| 2018-06-30 | 77 | -69 | -150 |
| 2018-03-31 | 107 | -9 | -117 |
| 2017-12-31 | 115 | 8 | -96 |
| 2017-09-30 | 90 | 1 | -117 |
| 2017-06-30 | 89 | -93 | -105 |
| 2017-03-31 | 57 | -150 | -142 |
| 2016-12-31 | 49 | -143 | -157 |
| 2016-09-30 | 53 | -141 | -156 |
| 2016-06-30 | 60 | -124 | -145 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (1 month ago) | See Below |
| Future Estimates | Average of up to 10 Analyst Estimates (S&P Global) | See Below |
All data from ImmunoGen Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | -0.59 | -0.15 | -0.96 | 7.00 |
| 2022-12-31 | -0.78 | -0.36 | -1.34 | 7.00 |
| 2021-12-31 | -0.91 | -0.56 | -1.20 | 8.00 |
| 2020-12-31 | -0.93 | -0.66 | -1.22 | 10.00 |
| 2019-12-31 | -1.06 | -0.74 | -1.27 | 10.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2019-03-31 | -1.21 |
| 2018-12-31 | -1.21 |
| 2018-09-30 | -1.04 |
| 2018-06-30 | -1.24 |
| 2018-03-31 | -1.08 |
| 2017-12-31 | -0.98 |
| 2017-09-30 | -1.32 |
| 2017-06-30 | -1.21 |
| 2017-03-31 | -1.63 |
| 2016-12-31 | -1.80 |
| 2016-09-30 | -1.79 |
| 2016-06-30 | -1.67 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if ImmunoGen will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Future performance checks
We assess ImmunoGen's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
ImmunoGen has a total score of 2/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
IMGN Past Performance
How has ImmunoGen performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- ImmunoGen does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- Unable to compare ImmunoGen's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare ImmunoGen's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
All data from ImmunoGen Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2019-03-31 | 42.22 | -173.98 | 37.53 | |
| 2018-12-31 | 53.45 | -168.84 | 36.75 | |
| 2018-09-30 | 79.48 | -140.16 | 36.04 | |
| 2018-06-30 | 77.03 | -150.04 | 35.60 | |
| 2018-03-31 | 106.76 | -117.28 | 35.79 | |
| 2017-12-31 | 115.45 | -96.01 | 33.91 | |
| 2017-09-30 | 89.85 | -117.05 | 33.40 | |
| 2017-06-30 | 89.03 | -105.10 | 34.95 | |
| 2017-03-31 | 57.41 | -142.15 | 35.41 | |
| 2016-12-31 | 48.63 | -156.73 | 38.53 | |
| 2016-09-30 | 52.81 | -155.81 | 38.05 | |
| 2016-06-30 | 60.00 | -144.82 | 33.62 | |
| 2016-03-31 | 65.21 | -129.37 | 34.88 | |
| 2015-12-31 | 56.92 | -119.06 | 30.64 | |
| 2015-09-30 | 87.19 | -72.20 | 29.46 | |
| 2015-06-30 | 85.54 | -60.74 | 28.23 | |
| 2015-03-31 | 78.67 | -56.76 | 27.42 | |
| 2014-12-31 | 74.12 | -72.60 | 26.46 | |
| 2014-09-30 | 55.88 | -82.42 | 25.04 | |
| 2014-06-30 | 59.90 | -71.36 | 24.47 | |
| 2014-03-31 | 57.98 | -66.74 | 23.39 | |
| 2013-12-31 | 76.11 | -30.64 | 22.34 | |
| 2013-09-30 | 48.66 | -58.85 | 22.36 | |
| 2013-06-30 | 35.54 | -72.81 | 21.47 | |
| 2013-03-31 | 34.66 | -73.35 | 26.62 | |
| 2012-12-31 | 12.91 | -90.67 | 26.65 | |
| 2012-09-30 | 17.91 | -79.03 | 26.02 | |
| 2012-06-30 | 16.36 | -73.32 | 20.42 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if ImmunoGen has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
- It is difficult to establish if ImmunoGen has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if ImmunoGen improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess ImmunoGen's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
ImmunoGen has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
IMGN Health
How is ImmunoGen's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up ImmunoGen's finances.
The net worth of a company is the difference between its assets and liabilities.
- ImmunoGen is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- ImmunoGen's long term commitments exceed its cash and other short term assets.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- ImmunoGen has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from ImmunoGen Company Filings, last reported 1 month ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2019-03-31 | -27.60 | 28.79 | 270.40 |
| 2018-12-31 | 10.97 | 2.06 | 262.25 |
| 2018-09-30 | 46.89 | 2.06 | 303.21 |
| 2018-06-30 | 89.19 | 2.06 | 345.06 |
| 2018-03-31 | -36.31 | 2.05 | 218.38 |
| 2017-12-31 | -17.90 | 2.05 | 267.11 |
| 2017-09-30 | -111.30 | 3.02 | 194.85 |
| 2017-06-30 | -173.23 | 97.30 | 150.34 |
| 2017-03-31 | -167.53 | 97.13 | 126.57 |
| 2016-12-31 | -152.85 | 96.97 | 159.96 |
| 2016-09-30 | -122.54 | 96.79 | 196.00 |
| 2016-06-30 | -82.30 | 96.63 | 245.03 |
| 2016-03-31 | -41.14 | 0.00 | 182.91 |
| 2015-12-31 | -16.69 | 0.00 | 212.28 |
| 2015-09-30 | 11.61 | 0.00 | 247.84 |
| 2015-06-30 | 35.10 | 0.00 | 278.11 |
| 2015-03-31 | 59.67 | 0.00 | 111.83 |
| 2014-12-31 | 77.47 | 0.00 | 106.60 |
| 2014-09-30 | 58.97 | 0.00 | 121.80 |
| 2014-06-30 | 75.70 | 0.00 | 142.26 |
| 2014-03-31 | 97.93 | 0.00 | 164.08 |
| 2013-12-31 | 130.04 | 0.00 | 178.09 |
| 2013-09-30 | 119.44 | 0.00 | 174.84 |
| 2013-06-30 | 121.85 | 0.00 | 194.96 |
| 2013-03-31 | 139.00 | 0.00 | 206.10 |
| 2012-12-31 | 136.00 | 0.00 | 211.02 |
| 2012-09-30 | 157.31 | 0.00 | 233.61 |
| 2012-06-30 | 83.89 | 0.00 | 160.94 |
- ImmunoGen has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
- Irrelevant to check if ImmunoGen's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- ImmunoGen has sufficient cash runway for 2.4 years based on current free cash flow.
- ImmunoGen has sufficient cash runway for 2.6 years if free cash flow continues to reduce at historical rates of -10.8% each year.
Financial health checks
We assess ImmunoGen's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) ImmunoGen has a total score of 3/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
IMGN Dividends
What is ImmunoGen's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
$2,000 of
ImmunoGen
shares you are expected to receive
$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate ImmunoGen's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate ImmunoGen's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 10 Analyst Estimates (S&P Global) | See Below |
| Global Biotechs Industry Average Dividend Yield | Market Cap Weighted Average of 19 Stocks | 2.4% |
| United States of America Market Average Dividend Yield | Market Cap Weighted Average of 2005 Stocks | 2.5% |
| United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.4% |
| United States of America Top 25% Dividend Yield | 75th Percentile | 3.7% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-12-31 | ||
| 2022-12-31 | ||
| 2021-12-31 | ||
| 2020-12-31 | ||
| 2019-12-31 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as ImmunoGen has not reported any payouts.
- Unable to verify if ImmunoGen's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess ImmunoGen's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can ImmunoGen afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) ImmunoGen has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
IMGN Management
CEO
| COMPENSATION | $8,823,242 |
| AGE | 54 |
| TENURE AS CEO | 3 years |
CEO Bio
Mr. Mark J. Enyedy has been the Chief Executive Officer and President at ImmunoGen, Inc. since May 16, 2016 and has been its interim principal financial officer since November 26, 2018. Mr. Enyedy has over 25 years of combined general management, business development and legal experience in the biotechnology industry across multiple therapeutic areas. He served as Head of Corporate Development at Shire plc since January 1, 2015 to until May 13, 2016 and served as its Company Secretary and Executive Vice President. He joined Shire in 2013 and served as its Internal Medicine Business Unit Head from August 2013 to April 2014. Mr. Enyedy served as the Interim General Counsel of Shire plc from January 1, 2015 to June 15, 2015 and led its Strategy, M&A and Corporate Planning functions and provided commercial oversight for its pre-Phase 3 portfolio. He served as the Chief Executive Officer of Proteostasis Therapeutics, Inc from 2011 to 2013. He joined Proteostasis after serving 15 years at Genzyme Corporation. He began his career at Genzyme Corporation in 1996 as Corporate Counsel, where he was responsible for overseeing corporate collaborations, merger and acquisition activities, financings and securities law compliance. During his tenure at Genzyme, Mr. Enyedy developed and executed its strategy to enter the oncology market and oversaw the launch of two new products and managing a global business generating over $675 million in revenue with operations in more than 50 countries. He served as the President of Transplant, Oncology & multiple sclerosis divisions and Senior Vice President at Genzyme Corporation. Mr. Enyedy served as President for Genzyme Oncology, Inc. Mr. Enyedy served as Senior Vice President and General Manager of Genzyme Molecular Oncology at Genzyme Corporation since July 16, 2003. He served as Vice President of Business Development for Genzyme Corporation, where he completed over twenty transactions, including Purdue Pharma L.P. He provided senior level transactional support for Genzyme Corporation's other therapeutic franchises. Mr. Enyedy served as the Director of Business Development in Genzyme's Oncology Division. He served as Vice President of Business Development at Vertex Pharmaceuticals Incorporated since February 3, 2003. He oversaw Vertex’s business development organization at its Cambridge, MA, headquarters. From 1990 to 1996, he worked as an Associate in the business law department at Palmer & Dodge, LLP, where he represented biopharmaceutical companies in acquisition, partnering and financing transactions. He is a Director of Akebia Therapeutics, Inc. since December 12, 2018. He was an Independent Director at Keryx Biopharmaceuticals, Inc. since September 13, 2017 until December 12, 2018. He has been a Director of ImmunoGen, Inc. since May 16, 2016. He was a Director of Fate Therapeutics, Inc. since July 2012 until May 2, 2018. He served as a Director of Proteostasis Therapeutics, Inc. Mr. Enyedy holds a BS in criminal justice from Northeastern University and a J.D. from Harvard Law School.
CEO Compensation
- Mark's compensation has increased whilst company is loss making.
- Mark's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the ImmunoGen management team in years:
- The tenure for the ImmunoGen management team is about average.
Management Team
Mark Enyedy
President
$9M
54
3 yrs
Rich Gregory
Executive VP & Chief Scientific Officer
$2M
60
4.3 yrs
Craig Barrows
Executive VP
$2M
63
11.6 yrs
Blaine McKee
Executive VP & Chief Business Officer
$2M
53
1.1 yrs
David Foster
VP of Finance & Chief Accounting Officer
Sarah Kiely
Investor Relations & Corporate Communications Officer
Audrey Bergan
VP & Chief Human Resources Officer
0.8 yrs
Theresa Wingrove
Senior Vice President of Regulatory Affairs & Quality
60
Anna Berkenblit
Senior VP & Chief Medical Officer
$999K
48
4.1 yrs
Courtney O’Konek
Director of Corporate Communications
Board of Directors Tenure
Average tenure and age of the ImmunoGen board of directors in years:
- The tenure for the ImmunoGen board of directors is about average.
Board of Directors
Stephen McCluski
Chairman
$267K
66
9.5 yrs
Mark Enyedy
President
$9M
54
3 yrs
Kris Peterson
Independent Director
$237K
59
7.3 yrs
Dean Mitchell
Independent Director
$231K
62
7.3 yrs
Richard Wallace
Independent Director
$234K
67
11.5 yrs
Mark Goldberg
Independent Director
$227K
64
7.5 yrs
Stuart Arbuckle
Director
$428K
52
1.3 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price ($) | Value ($) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 07. Nov 18 | Buy | Mark Goldberg | Individual | 06. Nov 18 | 06. Nov 18 | 30,000 | $5.76 | $172,800 | ||
Management checks
We assess ImmunoGen's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) ImmunoGen has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
IMGN News
Simply Wall St News
How Should Investors React To ImmunoGen, Inc.'s (NASDAQ:IMGN) CEO Pay?
First, this article will compare CEO compensation with compensation at similar sized companies. … Check out our latest analysis for ImmunoGen How Does Mark Enyedy's Compensation Compare With Similar Sized Companies? … As you can see, Mark Enyedy is paid more than the median CEO pay at companies of a similar size, in the same market.
Simply Wall St - – Full articleWhat Kind Of Shareholder Owns Most ImmunoGen, Inc. (NASDAQ:IMGN) Stock?
Generally speaking, as a company grows, institutions will increase their ownership. … Conversely, insiders often decrease their ownership over time. … Taking a look at our data on the ownership groups (below), it's seems that.
Simply Wall St - – Full articleImmunoGen, Inc. (NASDAQ:IMGN): Is It A Good Long Term Opportunity?
ImmunoGen, Inc.'s (NASDAQ:IMGN) announced its latest earnings update in December 2018, which … company earnings became less negative compared to the previous year's level
Simply Wall St - – Full articleDoes ImmunoGen, Inc.'s (NASDAQ:IMGN) CEO Pay Compare Well With Peers?
In 2016 Mark Enyedy was appointed CEO of ImmunoGen, Inc. … This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Mark Enyedy's Compensation Compare With Similar Sized Companies?
Simply Wall St - – Full articleHow Many Insiders Sold ImmunoGen, Inc. (NASDAQ:IMGN) Shares?
We often see insiders buying up shares in companies that perform well over the long term. … (NASDAQ:IMGN), you may well want to know whether insiders have been buying or selling. … As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.'.
Simply Wall St - – Full articleCan We See Significant Institutional Ownership On The ImmunoGen, Inc. (NASDAQ:IMGN) Share Register?
Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … We also tend to see lower insider ownership in companies that were previously publicly owned. … Our analysis of the ownership of the company, below, shows that.
Simply Wall St - – Full articleIs ImmunoGen Inc's (NASDAQ:IMGN) CEO Overpaid Relative To Its Peers?
This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Mark Enyedy's Compensation Compare With Similar Sized Companies. … We examined companies with market caps from US$400m to US$1.6b, and discovered that the median CEO compensation of that group was US$2m
Simply Wall St - – Full articleOne Thing To Consider Before Buying ImmunoGen Inc (NASDAQ:IMGN)
Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.
Simply Wall St - – Full articleIs There An Opportunity With ImmunoGen Inc's (NASDAQ:IMGN) 31.86% Undervaluation?
by taking the foreast future cash flows of the company and discounting them back to today's value. … discounted cash flows (DCF). … If you want to learn more about discounted cash flow, the basis for my calcs can be read in detail in the Simply Wall St analysis model
Simply Wall St - – Full articleWhat Are Analysts Expecting From ImmunoGen Inc (NASDAQ:IMGN) In The Year Ahead?
After ImmunoGen Inc's (NASDAQ:IMGN) earnings announcement in December 2017, analyst forecasts appear to be bearish, with earnings expected to decline by -52.73% in the upcoming year. … With net income at current levels of -US$96.01M, the consensus growth rate suggests that earnings will decline to -US$45.38M by 2019. … To reduce the year-on-year volatility of analyst earnings forecast, I've inserted a line of best fit through the expected earnings figures to determine the annual growth rate from the slope of the line.
Simply Wall St - – Full articleIMGN Company Info
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. ImmunoGen, Inc. has collaborations with Roche, Amgen/Oxford BioTherapeutics, sanofi-aventis U. S. LLC, Biotest AG, Bayer HealthCare AG, Novartis Institutes for BioMedical Research, Inc., CytomX Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Fusion Pharmaceuticals Inc., Debiopharm International SA, Jazz Pharmaceuticals Ireland Limited, and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Details
| Name: | ImmunoGen, Inc. |
| IMGN | |
| Exchange: | NasdaqGS |
| Founded: | 1980 |
| $288,594,725 | |
| 149,530,946 | |
| Website: | http://www.immunogen.com |
| Address: |
ImmunoGen, Inc. 830 Winter Street, Waltham, Massachusetts, 02451, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NasdaqGS | IMGN | Common Stock | Nasdaq Global Select | US | USD | 17. Nov 1989 | |
| DB | IMU | Common Stock | Deutsche Boerse AG | DE | EUR | 17. Nov 1989 |
Number of employees
Current staff
Industry
| Biotechnology | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/05/23 04:08 |
| End of day share price update: | 2019/05/22 00:00 |
| Last estimates confirmation: | 2019/05/16 |
| Last earnings filing: | 2019/05/07 |
| Last earnings reported: | 2019/03/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
